STENDRA (AVANAFIL) TABLETS

Serial Number 87376446
602

Registration Progress

Application Filed
Mar 18, 2017
Under Examination
Oct 31, 2017
Approved for Publication
Sep 5, 2017
Published for Opposition
Sep 5, 2017
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: STENDRA (AVANAFIL) TABLETS
Previous Owner: Metuchen Pharmaceuticals LLC
Classes: 005

Trademark Image

STENDRA (AVANAFIL) TABLETS

Basic Information

Serial Number
87376446
Filing Date
March 18, 2017
Published for Opposition
September 5, 2017
Abandonment Date
January 4, 2019
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Jan 29, 2019
Classes
005

Rights Holder

Metuchen Pharmaceuticals LLC

16
Address
1st floor
11 Commerce Drive
Cranford, NJ 07016

Ownership History

Metuchen Pharmaceuticals LLC

Original Applicant
16
Cranford, NJ

Metuchen Pharmaceuticals LLC

Owner at Publication
16
Cranford, NJ

Legal Representation

Attorney
Mark Pohl

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

35 events
Date Code Type Description Documents
Jan 30, 2019 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Jan 29, 2019 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Jul 3, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 3, 2018 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jul 3, 2018 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Apr 12, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 25, 2018 IUAF S USE AMENDMENT FILED Loading...
Apr 12, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 25, 2018 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Oct 31, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 5, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 5, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 16, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 24, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 24, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 24, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 24, 2017 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jul 24, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 22, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 22, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 22, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 28, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 28, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 28, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 27, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 27, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 27, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 23, 2017 GEAN O NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED Loading...
Jun 23, 2017 GEAP F EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED Loading...
Jun 23, 2017 EPEN O COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY Loading...
Jun 23, 2017 CPEA R EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED Loading...
Jun 12, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 24, 2017 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Mar 23, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 22, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals for the treatment of erectile dysfunction and sexual dysfunctions and disorders, and for the maintenance of sexual health, for use in the treatment and prevention of incontinence, for treatment of prostate and urinary tract diseases and disorders, for treatment of cardiovascular or endothelial disease, disorders or dysfunction, for treatment of neurodegenerative diseases, and for memory enhancement
First Use Anywhere: Mar 25, 2018
First Use in Commerce: Mar 25, 2018

Additional Information

Design Mark
The mark consists of the stylized term "STENDRA" in silver with the appearance of brushed metal. The term "STENDRA" is partially outlined in copper and yellow and includes partial shadowing in grey. A split curved line design in the colors orange, copper and silver appears to the right of the term "STENDRA" with radiating lines in various shades of yellow, orange and copper appearing behind the term "STENDRA". The silver wording "(AVANAFIL) TABLETS" appears underneath the term "STENDRA".
Color Claim
The color(s) silver, yellow, orange, copper and grey is/are claimed as a feature of the mark.
Other
The mark was first used anywhere in a different form other than that sought to be registered at least as early as 12/27/2013
Other
The mark was first used in commerce in a different form other than that sought to be registered at least as early as 12/27/2013

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"AVANAFIL TABLETS"